NRC Form 374 (5-84) CORRECTED COPY

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 21

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Kent General Hospital	In accordance with letter dated June 2, 1986, 3. License number 07-14850-01 is amended in its entirety to read as follows:
2. 640 South Governors Avenue Dover, Delaware 19901	4. Expiration date October 31, 1987
	5. Docket or Reference No. 030-07565

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 3 curies of each byproduct material authorized in Subitem 6.B.
C. Xenon 133	C. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	C. 200 millicuries
D. Americium 241	D. Sealed Source	D. 2 millicuries

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 07-14850-01
Docket or Reference number 030-07565

CORRECTED COPY

Amendment No. 21

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100, Title 10, Code of Federal Regulations.
B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
C. Blood flow and pulmonary function studies.
D. For use as an Anatomical marker.

CONDITIONS

10. Licensed material shall be used only at 640 South Governors Avenue, Dover, Delaware.

11. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Mahendra Parikh, M.D.	Groups I, II and III Xenon 133 Americium 241 as an anatomical marker
Kisan Y. Karapurkar, M.D.	Groups I, II and III Xenon 133 Americium 241 as an anatomical marker
Craig L. Taylor, M.D.	Groups I, II and III Xenon 133 Americium 241 as an anatomical marker

12. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

B. Before disposal as normal waste, radioactive waste shall be surveyed to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

13. For a period not to exceed 60 days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

A. Has the prior written permission of the hospital's Administrator and Radiation Safety Committee, and

B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 07-14850-01
Docket or Reference number 030-07565

CORRECTED COPY

Amendment No. 21

(13. continued) CONDITIONS

C. Performs only those procedures which the physician is specifically authorized to perform pursuant to a license issued by the Nuclear Regulatory Commission.

The licensee shall maintain for inspection by the Commission copies of the written permission specified in A. above and of the license(s) specified in B. and C. above for a period of 5 years from the date permission is granted under A. above.

14. A(1) The sources or detector cells specified in Item 7.D shall be tested for leakage and/or contamination at intervals not to exceed 6 months. Any source or detector cell received from another person which is not accompanied by a certificate indicating that a test was performed within 6 months before the transfer shall not be put into use until tested.

(2) Notwithstanding the periodic leak test required by this condition, any licensed sealed source or detector cell is exempt from such leak tests when the source or detector cell contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material.

B. Any source or detector cell in storage and not being used need not be tested. When the source or detector cell is removed from storage for use or transfer to another person, it shall be tested before use or transfer.

C. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, the source or detector cell shall be removed from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. A report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region I, ATTN: Chief, Nuclear Materials Safety and Safeguards Branch, 631 Park Avenue, King of Prussia, Pennsylvania 19406. The report shall specify the source involved, the test results, and corrective action taken. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Commission. Records may be disposed of following Commission inspection.

D. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to perform such services.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 07-14850-01
Docket or Reference number: 030-07565

CORRECTED COPY

Amendment No. 21

(continued) CONDITIONS

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated March 17, 1982
B. Letter dated August 30, 1982
C. Letter received April 1, 1983
D. Letter received July 20, 1983
E. Letter dated August 18, 1983
F. Letter dated June 2, 1986
G. Letter dated July 14, 1986

Date 26 AUG 1987

For the U.S. Nuclear Regulatory Commission
Original Signed By:
Jack Davis
By _____
Nuclear Materials Safety and
Safeguards Branch, Region I
King of Prussia, Pennsylvania 19406